PAVmed Inc. PAVM
PAVmed Inc. (Nasdaq: PAVM) is a GI/hepatology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EsoGuard / EsoCheck (Lucid Diagnostics) | Esophageal precancer and cancer screening (CLIA LDT; EsoCheck 510(k)-cleared) | unclear | NA_NON_THERAPEUTIC |
| Veris Cancer Care Platform and implantable physiological monitor (Veris Health) | Digital cancer care monitoring | device-combination | NA_NON_THERAPEUTIC |
| PortIO implantable intraosseous vascular access device | Vascular access via bone marrow cavity | device-combination | NA_NON_THERAPEUTIC |
| a/LCI plus OCT endoscopic imaging probe (licensed from Duke University) | Identification of advanced esophageal dysplasia | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.